Publication:
Stereotactic ablative radiotherapy (SABR) in operable early stage non-small cell lung cancer (NSCLC) patients: challenge to claim being undisputed gold standard

Simple item page
dc.contributor.coauthorYalman, Deniz
dc.contributor.departmentSchool of Medicine
dc.contributor.facultymemberYes
dc.contributor.kuauthorSelek, Uğur
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T23:36:42Z
dc.date.issued2015
dc.description.abstractThe standard treatment for operable, early stage non-small cell lung cancer (NSCLC) is surgical resection, usually lobectomy, with mediastinal lymph node sampling or dissection. However, significant surgical toxicity had been noted in these patients with 90-day mortality rates exceeding 30-day rates. There is also a risk of disease recurrence ranging from 6% to 10% per person-year during the first 4 years after surgery as stated by Lou et al. after an analysis of 1,300 patients who underwent surgery.eng
dc.description.fulltextNo
dc.description.harvestedfromManual
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.openaccessNO
dc.description.peerreviewstatusN/A
dc.description.publisherscopeInternational
dc.description.readpublishN/A
dc.description.sponsoredbyTubitakEuN/A
dc.description.versionN/A
dc.identifier.doi10.3978/j.issn.2305-5839.2015.06.23
dc.identifier.eissn2305-5847
dc.identifier.embargoN/A
dc.identifier.issn2305-5839
dc.identifier.issue11
dc.identifier.pubmed26244137
dc.identifier.quartileN/A
dc.identifier.scopus2-s2.0-85015483458
dc.identifier.urihttps://doi.org/10.3978/j.issn.2305-5839.2015.06.23
dc.identifier.urihttps://hdl.handle.net/20.500.14288/12692
dc.identifier.volume3
dc.identifier.wos000218801500003
dc.keywordsStereotactic ablative radiotherapy
dc.keywordsNon-small cell lung cancer
dc.keywordsNSCLC
dc.keywordsLobectomy
dc.keywordsEarly stage lung cancer
dc.keywordsOperable patients
dc.keywordsLocal control
dc.keywordsSurvival
dc.language.isoeng
dc.publisherAME Publishing Company
dc.relation.affiliationKoç University
dc.relation.collectionKoç University Institutional Repository
dc.relation.ispartofAnnals of Translational Medicine
dc.relation.openaccessN/A
dc.rightsN/A
dc.subjectOncology
dc.subjectRadiation oncology
dc.subjectPulmonary medicine
dc.titleStereotactic ablative radiotherapy (SABR) in operable early stage non-small cell lung cancer (NSCLC) patients: challenge to claim being undisputed gold standard
dc.typeOther
dspace.entity.typePublication
local.contributor.kuauthorSelek, Uğur
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files

Collections

Publications without Fulltext